Research & Development: Page 94
-
PharmaVoice Team/PharmaVoice
Table of Contents
Table of Contents June 2006 VIEW on Clinical Services Letter from the Editor The Forum A Rising Tide For Clinical Services: Contract drug-development expenditures were $19 billion in 2005 and are expected to increase at an annual rate of 17%, eventually exceeding $42 billion by 2010. Company List...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Don't Get Stopped Short by a Shortage of Study Drug - Good Project Management Can Keep Trials Running Smoothly
Clinical-Trial Managment June 2006 VIEW on Clinical Services Don’t Get Stopped Short by a Shortage of Study Drug – Good Project Management Can Keep Trials Running Smoothly Timothy J. Noffke, VP Life Sciences Managing a clinical trial can be a daunting endeavor, with significant factors...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Streamlining The Investigator-Initiated Trial Program
Streamlining The Investigator-Initiated Trial Program Nancy Bella, Pharm.D. Integration of an experienced clinical services agency as the driving force of investigator-initiated trials, can bridge the gap between the pharmaceutical company and the investigator,...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Practice Makes Perfect -- E-Clinical Trial Standardization
The E-Arena June 2006 VIEW on Clinical Services Practice Makes Perfect — E-Clinical Trial Standardization John Cline, CEO By having data in set formats, identifying trends and reporting key pieces of information across multiple trials will be possible. And that’s key ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Improving Efficiency in Clinical Development How to Build and Manage an Environment of Continuous Improvement
Improving Efficiency in Clinical Development How to Build and Manage an Environment of Continuous Improvement Most clinical leaders deeply understand the need to improve efficiency. The next step is motivating themselves and their organizations to tackle the changes ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
FDA Draft Guidance Impact on the E-PRO Industry Contributed by Dr. Richard Piazza As some treatment effects are only known to the subject enrolled in a study, patient-reported outcome (PRO) measures have become a common metric in determining treatment efficacy and safety in clinical trials. Advan...
By Dr. Richard Piazza • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Stepping Up to Challenges Across the Board -- Theresa Kane Musser
Stepping Up to Challenges Across the Board For every idea and opinion, there are contrary points of view; this give and take is what feeds innovation, propels scientific thinking and discovery, and creates rounded, well-adjusted teams and companies. It’s a perspective that Theresa Kane Musser emb...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
GE Healthcare Launches Laboratory Assets System GE Healthcare has introduced Scientific Asset Services, a laboratory asset services offering that can save pharmaceutical and biotechnology companies up to 20% of their total service costs and optimize service operations. Scientific Asset Services p...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
Your Source for Life-Sciences Events and Conference Information Professional education is an ongoing endeavor for most executives. PharmaVOICE has partnerships with every major conference provider serving the life-sciences industry. PharmaVOICE is distributed at more than 150 industry events a ye...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Meeting the Needs of Patients with Rare Diseases
Incentives designed to bring drugs to the market to treat rare diseases have been successful, yielding 280 products, but there are still many patients without adequate treatment. The National Institutes of Health Office of Rare Diseases (ORD) lists more than 6,000 rare diseases affecting an estim...
By Cynthia Borda • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
A Rising Tide for Clinical Services
A Rising Tide for Clinical Services By Daniel Limbach June 2006 VIEW on Clinical Services Contract drug-development expenditures were $19 billion in 2005 and are expected to increase at an annual rate of 17%, eventually exceeding $42 billio...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Meet the R&D Leaders
By Denise Myshko Executives charged with R&D responsibilities within biotech and pharmaceutical organizations, both large and small, face myriad opportunities and challenges. Drug development is a costly and risky business. The pharmaceutical industry is challenged by many factors related to ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
UpFront
Office Visits — The Doctor Is In Docs Want More from Rep Calls Pfizer, Novartis, and GlaxoSmithKline have been identified as three companies whose sales reps are doing the best job of meeting the needs of physicians, but a TNS Healthcare study finds that there is room for improvement across the b...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
What's New
Ventiv Health Changes Name to Reflect Broader Capabilities Rebranding initiative integrates inChord nomenclature to more clearly communicate services. Ventiv Health Inc. has changed its corporate brand name to inVentiv Health as part of a rebranding initiative that began when Ventiv acquired inCh...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Opportunities and Challenges for Pharma R&D in China China will likely surpass many Western European markets to emerge as the world’s fifth-largest national market for pharmaceuticals by 2010. Biopharma research and development in Ch...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
A Journey of a Lifetime -- Leslie Williams
Leslie Williams, the president and CEO of Ventaira Pharmaceuticals, is driven by a desire to advance the frontiers of medicine. She melds that goal with a passion for life, a dedication to family, and pure, unadulterated hard work. May 2006 PharmaVOICE A Journey of a Lifetime — Leslie Williams Le...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Combination Products: Drugs and Devices
The possibilities are endless. Emerging drug-delivery technologies and smarter drug-development strategies are providing a one-two punch for researchers and marketers who envision scientific advancements that could span multiple therapeutic categories. By Denise Myshko In the broadest sense, phar...
By Denise Myshko • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
May 10 2006 HBA Woman of the Year Luncheon Hilton New York, New York For more information, contact Healthcare Businesswomen’s Association at 973-575-0606, e-mail [email protected], or visit hbanet.org. May 10-12 PharmaDiscovery Bethesda North Marriott Hotel & Conference Center, North Bethesda...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
On the Cover Creative marketing: New challenges, new tools, new attitudes Marketers are turning to a vast array of tools to meet today’s challenges. The hot tools are predominately patient focused instead of the broader, mass- marketing approach of DTC. FEATURES Combination products: Drugs and de...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
UpFront
Biotech pioneer recognized Dr. Zaffaroni Receives 2006 Biotech Heritage Award The Chemical Heritage Foundation (CHF) and Biotechnology Industry Organization (BIO) presented the 8th Annual Biotechnology Heritage Award to Alejandro Zaffaroni, a pioneer of the biotechnology revolution and a legendar...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
A Model for Success
Alternatives to the integrated pharmaceutical company business model — such as development-only or hybrid models — are taking hold as smaller players contribute to the industry’s value chain. Ansbert Gadicke MPM Capital The development-only business model makes complete sense, but it is extremely...
By Denise Myshko • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
New Electronic and Web-based Applications, Sites, and Technologies McGraw-Hill’s Access Medicine Launches Online Neurology Resource McGraw-Hill Medical Publishing has released Adams and Victor’s Principles of Neurology on its AccessMedicine.com platform. Adams and Victor’s Principles of Neurology...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In this day and age when individuals are granted almost instant cult status based on subjective, if not dubious, talent, the “star” label can sometimes lose its luster. And while we live in a cynical world, where the next American Idol is about to be crowned by millions of Americans, it’s nice to...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Avoiding Undue Influence
Thought leaders — scientific and clinical experts — play a pivotal role in helping pharma companies identify key topics of interest to physicians. Depending on their role, these KOLs provide launch and sales support or play a critical role in continuing medical education. They provide solid, evid...
By Autumn Konopka • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
What's on Your Mind -- Opinions
Alternatives to the integrated pharmaceutical company business model are taking hold as smaller players contribute to the industry’s value chain. Some of these newer players are focusing on specific areas, such as development, while others are creating hybrid models. We asked PharmaVOICE readers ...
By PharmaVoice Team • Jan. 2, 2008
Previous
